Thomas A Angelovich1, Anna C Hearps, Anna Maisa, Genevieve E Martin, Gregor F Lichtfuss, Wan-Jung Cheng, Clovis S Palmer, Alan L Landay, Suzanne M Crowe, Anthony Jaworowski. 1. *Centre for Biomedical Research, Burnet Institute, Melbourne, Australia; †School of Applied Sciences, RMIT University, Melbourne, Australia; ‡Department of Infectious Diseases, Monash University, Melbourne, Australia; §School of Medical Sciences, University of New South Wales, Sydney, Australia; ‖Department of Microbiology and Immunology, Rush University Medical Center, Chicago, IL; ¶Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia; and #Department of Immunology, Monash University, Melbourne, Australia.
Abstract
BACKGROUND: Chronic inflammation and immune activation occur in both HIV infection and normal aging and are associated with inflammatory disease. However, the degree to which HIV influences age-related innate immune changes, and the biomarkers which best reflect them, remains unclear. METHODS AND RESULTS: We measured established innate immune aging biomarkers in 309 individuals including 88 virologically suppressed (VS) and 52 viremic (viral load ≤ and >50 copies per milliliter, respectively) HIV-positive individuals. Levels of soluble (ie, CXCL10, soluble CD163, neopterin) and cellular (ie, proportions of inflammatory CD16 monocytes) biomarkers of monocyte activation were increased in HIV-positive individuals and were only partially ameliorated by viral suppression. Viremic and VS HIV-positive individuals show levels of age-related monocyte activation biomarkers that are similar to uninfected controls aged 12 and 4 years older, respectively. Viremic HIV infection was associated with an accelerated rate of change of some monocyte activation markers (eg, neopterin) with age, whereas in VS individuals, subsequent age-related changes occurred at a similar rate as in controls, albeit at a higher absolute level. We further identified CXCL10 as a robust soluble biomarker of monocyte activation, highlighting the potential utility of this chemokine as a prognostic marker. IMPLICATIONS: These findings may partially explain the increased prevalence of inflammatory age-related diseases in HIV-positive individuals and potentially indicate the pathological mechanisms underlying these diseases, which persist despite viral suppression.
BACKGROUND: Chronic inflammation and immune activation occur in both HIV infection and normal aging and are associated with inflammatory disease. However, the degree to which HIV influences age-related innate immune changes, and the biomarkers which best reflect them, remains unclear. METHODS AND RESULTS: We measured established innate immune aging biomarkers in 309 individuals including 88 virologically suppressed (VS) and 52 viremic (viral load ≤ and >50 copies per milliliter, respectively) HIV-positive individuals. Levels of soluble (ie, CXCL10, soluble CD163, neopterin) and cellular (ie, proportions of inflammatory CD16 monocytes) biomarkers of monocyte activation were increased in HIV-positive individuals and were only partially ameliorated by viral suppression. Viremic and VS HIV-positive individuals show levels of age-related monocyte activation biomarkers that are similar to uninfected controls aged 12 and 4 years older, respectively. Viremic HIV infection was associated with an accelerated rate of change of some monocyte activation markers (eg, neopterin) with age, whereas in VS individuals, subsequent age-related changes occurred at a similar rate as in controls, albeit at a higher absolute level. We further identified CXCL10 as a robust soluble biomarker of monocyte activation, highlighting the potential utility of this chemokine as a prognostic marker. IMPLICATIONS: These findings may partially explain the increased prevalence of inflammatory age-related diseases in HIV-positive individuals and potentially indicate the pathological mechanisms underlying these diseases, which persist despite viral suppression.
Authors: Varghese K George; Suresh Pallikkuth; Rajendra Pahwa; Lesley R de Armas; Stefano Rinaldi; Li Pan; Savita Pahwa Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Simin Hua; Justin M Scott; David B Hanna; Sabina A Haberlen; Sanjiv J Shah; Howard N Hodis; Alan L Landay; Jason M Lazar; Jorge R Kizer; Bing Yu; Wendy S Post; Kathryn Anastos; Robert C Kaplan; Clary B Clish; Qibin Qi Journal: AIDS Date: 2019-05-01 Impact factor: 4.632
Authors: Signar Mäkitalo; Åsa Mellgren; Ellen Borgh; Lena Kilander; Tobias Skillbäck; Henrik Zetterberg; Magnus Gisslén Journal: AIDS Res Ther Date: 2015-07-14 Impact factor: 2.250
Authors: Felicia C Chow; Susan Regan; Markella V Zanni; Sara E Looby; Cheryl D Bushnell; James B Meigs; Steven K Grinspoon; Steve K Feske; Virginia A Triant Journal: AIDS Date: 2018-01-02 Impact factor: 4.177